What is the purpose and interpretation of the Montoux (Mantoux) test for tuberculosis (TB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

The Mantoux Test: Purpose and Interpretation for Tuberculosis Screening

The Mantoux test (PPD skin test) is the standard method for detecting latent tuberculosis infection, serving as a critical screening tool to identify individuals who may benefit from preventive therapy before developing active tuberculosis disease. 1

Administration Procedure

  • The Mantoux test is administered by injecting 0.1 ml of PPD (5 tuberculin units) intradermally into the volar or dorsal surface of the forearm, creating a 6-10 mm wheal 2, 1
  • The test must be read by trained healthcare personnel between 48-72 hours after injection 2, 1
  • Only the induration (hardened area) should be measured in millimeters, not the erythema (redness) 2, 3
  • Patient self-reading of results is unreliable and not recommended 2, 1
  • If the injection is administered incorrectly (subcutaneously or leaking from site), the test should be repeated immediately at another site 3

Interpretation of Results

The interpretation of PPD reactions depends on the risk profile of the individual being tested:

  • ≥5 mm induration is positive for high-risk individuals:

    • HIV-infected persons
    • Recent contacts of TB cases
    • Persons with fibrotic changes on chest X-ray consistent with prior TB
    • Immunosuppressed individuals (e.g., those on TNF-alpha inhibitors, organ transplant recipients) 2, 1
  • ≥10 mm induration is positive for moderate-risk individuals:

    • Recent immigrants from high TB prevalence countries
    • Injection drug users
    • Residents and employees of high-risk congregate settings (prisons, nursing homes)
    • Healthcare workers
    • Other populations with increased TB prevalence 2, 1
  • ≥15 mm induration is positive for persons with no known risk factors for TB 2, 1

Clinical Applications

  • The primary purpose is to identify latent TB infection in individuals who would benefit from preventive therapy 1
  • Essential for screening high-risk populations including healthcare workers, correctional facility residents, and immunocompromised patients 2, 1
  • Used in contact investigations after exposure to infectious TB cases 2
  • Helps guide decisions about preventive therapy to reduce progression to active TB disease 2

Follow-up Actions Based on Results

  • Negative test: No further action needed if the individual is not at high risk 1
  • Positive test: Requires chest radiography and clinical evaluation to exclude active TB before considering treatment for latent TB infection 2, 1
  • Contacts with initial negative tests: Should be retested 8-10 weeks after exposure ends, as conversion may be delayed 2

Special Considerations

Two-Step Testing

  • Recommended for baseline testing of healthcare workers and others who will undergo serial testing 1
  • Addresses the "booster phenomenon" where a first negative test may stimulate immunologic memory, causing a positive reaction on subsequent testing that could be misinterpreted as new infection 1
  • Second test should be administered 1-3 weeks after the first if initial test is negative 1

BCG Vaccination

  • History of BCG vaccination is not a contraindication to PPD testing 3
  • The larger the reaction to PPD, the greater the probability of true TB infection rather than BCG effect 3

Common Pitfalls and Limitations

  • Improper administration technique can lead to false-negative results 1, 3
  • Reading outside the 48-72 hour window reduces accuracy 2, 1
  • Poor return rates for test reading (up to 60% in some studies) compromise effectiveness 4
  • Limited specificity due to cross-reactivity with BCG vaccination and non-tuberculous mycobacteria 5
  • Newer interferon-gamma release assays (IGRAs) may be more specific, especially in BCG-vaccinated individuals 6, 5
  • Failure to consider risk factors when interpreting results can lead to inappropriate clinical decisions 1

Emerging Alternatives

  • Interferon-gamma release assays (IGRAs) are newer blood tests that measure T-cell response to TB-specific antigens 6, 5
  • IGRAs have higher specificity than the Mantoux test, particularly in BCG-vaccinated individuals 5
  • IGRAs require only a single visit, which may improve compliance compared to the Mantoux test 1

References

Guideline

PPD Screening for Tuberculosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tuberculin testing: placement and interpretation.

AAOHN journal : official journal of the American Association of Occupational Health Nurses, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.